You are here

Report: Emerging Treatments Offer Improvements in Lupus Therapy

Thought leaders see only modest efficacy benefits with belimumab (Apr. 2)

In a new survey conducted by the research and advisory firm Decision Resources, U.S. rheumatologists indicate that new therapies for systemic lupus erythematosus (SLE) that can positively differentiate themselves from current treatments in their effect on disease activity would be well received by physicians.

Based on currently available clinical data and thought-leader opinion, the emerging therapies epratuzumab (Immunomedics/UCB; a humanized monoclonal antibody) and forigerimod (Lupuzor, ImmuPharma; a peptide fragment analog) have the potential to offer improvements over intravenous (IV) belimumab (Benlysta, Human Genome Sciences/GlaxoSmithKline) in reducing disease activity. Thought leaders perceive belimumab to offer only modest efficacy benefits in patients who are refractory to conventional immunosuppressants.

According to the survey, both clinical data and thought-leader opinion suggest that the BAFF antagonist blisibimod (Anthera Pharmaceuticals) also shows the potential to reduce disease activity more effectively than IV belimumab in patients with severe SLE.

“Interviewed thought leaders consistently indicate a need for drugs with greater efficacy on disease activity, noting a variety of issues with currently available therapies,” said analyst Laura Croal, PhD. “In the case of the newest approved agent, IV belimumab, the efficacy benefit in moderate to severe SLE is perceived to be modest and slow to onset.”

The survey also finds that physicians in the U.S. identify new therapies with an improved effect on renal organ-domain scores as a key unmet need. Drugs typically used for the treatment of moderate-to-severe renal manifestations (including the SLE-related condition of lupus nephritis) are associated with a risk of serious adverse effects. Interviewed thought leaders acknowledged that the overall risk–benefit profile of these therapies limits their widespread use in patients with early and/or moderate signs of renal involvement.

Source: Decision Resources; April 2, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks